Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Core Viewpoint - Aipeng Medical (300753.SZ) has signed a partnership agreement to invest in a fund focused on brain-computer interfaces, neuroscience, and mental health, aiming to optimize its industry layout and leverage professional investment resources [1] Group 1: Investment Details - Aipeng Medical will invest RMB 49.7 million as a limited partner, representing a 49.7% stake in the investment fund [1] - The investment is directed towards sectors including brain-computer interfaces, neuroscience, mental health disorders, and other healthcare areas [1] Group 2: Strategic Objectives - The investment aims to accelerate the optimization of the company's industrial layout while ensuring that daily operations and development are not affected [1] - The partnership is designed to effectively control investment risks while leveraging the strengths of professional investment institutions [1]

Group 1 - The company announced a joint investment with Jiangsu Yingjue Private Equity Fund Management Co., Ltd. and Jiaxing Silin Venture Capital Partnership to establish Aipeng Zhilian Cloud Brain (Jiaxing) Equity Investment Partnership [1] - The company will act as a limited partner, contributing RMB 49.7 million, which represents a 49.7% stake in the investment fund [1] - The fund will primarily focus on equity investments in areas such as brain-computer interfaces, neuroscience, mental system diseases, and other healthcare sectors, with an investment period of 4 years and a total duration of 7 years [1]